免疫治疗相关毒性中类固醇减量策略的变异与结局
该单中心回顾性队列纳入2016年8月至2025年9月接受免疫检查点抑制剂(ICI)治疗的妇科恶性肿瘤患者,分析其发生需全身类固醇治疗的3-4级免疫相关不良事件(irAE)后类固醇减量方案与结局。共63例患者、73次减量,63.0%符合NCCN指南;不符合指南的减量更多需额外支持药物(81.5% vs 56.2%,p=0.0300),<28天减量更需额外支持药物(100% vs 57.6%,p=0.0027)和类固醇(35.7% vs 8.4%,p=0.0253)。
要点
- NCCN不一致减量更多需额外支持药物(81.5% vs 56.2%,p=0.0300)。
- <28天减量更需额外支持药物(100% vs 57.6%,p=0.0027)和类固醇(35.7% vs 8.4%,p=0.0253)。
- NCCN一致减量ICI再启动时间更长(56 vs 21天,p=0.0241)。
核心结论
- 妇科恶性肿瘤患者严重irAE的类固醇减量实践差异大,较短且不符合指南的减量方案与更多治疗升级和类固醇再启动相关。
研究设计与样本
- 单中心回顾性队列纳入2016年8月至2025年9月接受ICI治疗并发生需全身类固醇的3-4级irAE的妇科恶性肿瘤患者,共63例患者、73次类固醇减量。
主要发现
- 63.0%(46次)减量符合NCCN指南,37.0%(27次)不符合,不一致主要因减量时长和过早启动。
- NCCN不一致减量需额外支持药物比例高于一致减量(81.5% vs 56.2%,p=0.0300)。
- NCCN一致减量ICI再启动时间更长(56 vs 21天,p=0.0241)。
- <28天减量需额外支持药物(100% vs 57.6%,p=0.0027)和类固醇(35.7% vs 8.4%,p=0.0253)比例均高于≥28天减量。
- ≥28天减量因毒性停用ICI比例更高(59.3% vs 28.6%,p=0.0381);住院、ICU入住和AE缓解率无差异。
关键数值与推荐
- NCCN指南一致性评估及减量时长分组(<28天 vs ≥28天)。
临床怎么用
- 对妇科恶性肿瘤严重irAE患者,类固醇减量应参考NCCN指南并避免过短疗程,以减少治疗升级和类固醇再启动。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study examined both National Comprehensive Cancer Network (NCCN) guideline concordance and steroid taper duration with clinical outcomes in patients with gynecologic malignancies experiencing immune-related AEs. METHODS: This single-institution retrospective cohort included patients with gynecologic malignancies treated with immune checkpoint inhibitor (ICI) from August 2016 to September 2025 who developed grade 3 or 4 immune-related AEs requiring systemic steroids. Clinical and steroid treatment data were abstracted. NCCN guideline concordance and outcomes were assessed. RESULTS: 63 patients contributing 73 steroid tapers were included. Most patients had endometrial (41.3%), cervical (27.0%), or ovarian cancer (23.8%), and pembrolizumab was the most used ICI (74.6%). 46 tapers (63.0%) were NCCN guideline concordant and 27 (37.0%) were NCCN guideline discordant, with discordance most often driven by taper length and premature initiation. 14 (19.2%) were < 28 days, and 59 (80.8%) were ≥ 28 days. NCCN discordant tapers were more likely to require additional supportive medications for irAE management (e.g. secondary steroids) than concordant tapers (81.5% vs 56.2%, p = 0.0300). NCCN concordance was associated with longer time to ICI restart (56 vs 21 days, p = 0.0241). Tapers <28 days were more likely to require additional supportive medications (100% vs 57.6%, p = 0.0027) and steroids (35.7% vs 8.4%, p = 0.0253) than tapers ≥28 days. Tapers ≥28 days were associated with higher rates of ICI discontinuation due to toxicity (59.3% vs 28.6%, p = 0.0381). Rates of hospitalization, ICU admission, and AE resolution did not differ by NCCN concordance or taper duration. CONCLUSIONS: Corticosteroid taper practices varied substantially in patients with gynecologic malignancies experiencing severe irAEs; shorter and guideline-discordant tapers were associated with greater treatment escalation and steroid reinitiation.
引用
- Velasquez J, Chalif J, Glassman D, et al. How slow should we go? Variation and outcomes of steroid tapering for immunotherapy-related toxicities in gynecologic cancer. Gynecol Oncol. 2026. PMID: 42900968. doi:10.1016/j.ygyno.2026.10.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。